Laon

Researchers are studying the use of intrathecal ziconotide to treat patients with chronic non-cancer pain that does not respond to standard treatments. While ziconotide is mainly used for cancer-related pain with well-documented guidelines, its use for non-cancer pain is less understood because this group includes many different conditions. This study aims to provide information on patients with various types of non-malignant chronic pain, such as spinal cord injury, radiculopathy, diabetic neuropathy, complex regional pain syndrome, fibromyalgia, and others, by collecting data over the first two years of treatment. Participants will receive intrathecal ziconotide delivered through an internal pump surgically implanted by a trained neurosurgeon or anesthesiologist under general anesthesia. The study includes both patients already treated with ziconotide-based intrathecal analgesia and those new to this treatment who are candidates for starting or adding ziconotide to their pump therapy. The study monitors treatment use as per standard medical practice without altering the therapy. Throughout the study, researchers will collect detailed baseline information about patients’ demographics, medical history, pain characteristics, psychiatric and disability status, pain intensity, and prior pain management strategies. They will also track reasons for starting ziconotide and any planned changes to intrathecal treatment. This comprehensive data collection aims to better understand the types of patients receiving ziconotide and how they respond to this treatment over time.